Send me a link:

*Text messaging rates may apply.

 Dow Down0.42% Nasdaq Down0.39%

ProFunds Biotechnology UltraSector Inv (BIPIX)

54.92 Down 0.28(0.51%) Aug 1

Profile as of Jun 29, 2014Get Profile for:
ProFunds Biotechnology UltraSector Inv
Profunds3435 Stelzler RdColumbus, OH 43219
Map
Phone: 888-776-3637
Fund Overview 
Category:Trading-Leveraged Equity
Fund Family:ProFunds
Net Assets:446.22M
Year-to-Date Return:11.21%
Yield:0.00%
Morningstar Rating:4 stars
Fund Inception Date:Jun 19, 2000
Morningstar Style Box 
Trading-Leveraged Equity
[View Category Definition]
View Top Trading-Leveraged Equity Funds
About the Morningstar Style Box
Management Information 
Michael Neches
Lead Manager since Oct 1, 2013
Michael Neches, ProShare Advisors—Portfolio Manager as of December 2009; Associate Portfolio Manager from January 2007 through November 2009; and Portfolio Analyst from November 2004 to December 2006. ProFund Advisors—Portfolio Manager as of December 2009.
Investment Information 
Min Initial Investment:15,000
Min Initial Investment, IRA:15,000
Min Initial Investment, AIP:15,000
Min Subsequent Investment:N/A
Min Subsequent Investment, IRA:N/A
Min Subsequent Investment, AIP:N/A
BIPIX can be purchased from 82 brokerages.

Fund Summary 
The investment seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow Jones U.S. BiotechnologySM Index. The fund invests in securities and derivatives that the adviser believes, in combination, should have similar daily return characteristics as one and one-half times (1.5x) the daily return of the index. The index measures the performance of the biotechnology sector of the U.S. equity market. It is non-diversified.

Fund Operations 
Last Dividend : 0.00
Last Cap Gain (Dec 11, 2013) : 0.00
Annual Holdings Turnover (Jul 28, 2014) : 2.00%
Average for Category:293.25%
Fees & Expenses 
ExpenseBIPIXCategory Avg
Annual Report Expense Ratio (net):1.68%2.03%
Prospectus Net Expense Ratio:1.65%N/A
Prospectus Gross Expense Ratio:1.65%N/A
Max 12b1 Fee:0.00%N/A
Max Front End Sales Load:N/A4.75%
Max Deferred Sales Load: N/A1.00%
3 Yr Expense Projection*:520718
5 Yr Expense Projection*:8971,199
10 Yr Expense Projection*:1,9552,519
* Per $10,000 invested